GSK to buy US biotech firm IDRx for up to $1.15 billion
(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour. IDRx,
GSK to buy Boston-based IDRx for $1.15 billion
GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to $1.15 billion cash consideration. Under the agreement signed by both companies,
GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion
GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.
Drugmaker GSK Buys US Firm Focused On Gastro Cancer
British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specialises in the treatment of rare gastrointestinal cancer GIST.
GSK to acquire IDRx for $1B upfront
GSK (GSK) and IDRx announced that they have entered into an agreement under which GSK will acquire IDRx. Under the agreement, GSK will pay $1B
GSK to buy rare cancer drug developer IDRx for up to £1bn
Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million in 'success-based' milestone payments.
GSK to buy cancer-focused IDRx in $1 billion deal
Seeking to build up its cancer business, GSK said Monday it is buying the privately held U.S. biotech IDRx for $1 billion upfront.
GSK To Acquire GIST Drug Developer IDRx For Up To $1.15 Bln Cash
(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion in cash.
GSK falls Monday, underperforms market
Shares of GSK PLC GSK slipped 1.37% to £13.31 Monday, on what proved to be an all-around rough trading session for the stock ...
ENDPOINTS NEWS2h
GSK kicks off JPM deal­mak­ing with $1B+ buy­out of IDRx and its rare can­cer drug
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...
BioSpace7h
GSK Targets Rare Cancer With $1B+ Acquisition of IDRx
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
STAT5h
Pharmalittle: We’re reading about J&J and GSK deals, a departing FDA official, and more
J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...
FierceBiotech13h
JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...
devdiscourse6h
GSK's Major Biotech Acquisition Highlights Tumour Treatment Innovations
British drugmaker GSK plans to acquire US biotech firm IDRx for $1.15 billion, focusing on innovative tumour treatments.
GSK remains steady Friday, still outperforms market
GSK PLC GSK shares were unchanged Friday at £13.50, on what proved to be an all-around grim trading session for the stock ...
Ouro, backed by GSK, joins hunt to bring bispecifics to autoimmune disease
NEW YORK (PIX11) — A young man, homeless and disheveled, was surrounded by a joint response team made up of two NYPD officers ...